Alergia e Imunologia

[Preprint] Dados observacionais sugerem que a imunidade natural conferida pela infecção por SARS-CoV-2 é mais forte e duradoura em comparação à imunidade induzida por vacina.

30 Ago, 2021 | 12:57h

Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections – medRxiv

Comentário: Having SARS-CoV-2 once confers much greater immunity than a vaccine—but no infection parties, please – Science

 

Comentário no Twitter (fio – clique para saber mais)

Interesting and a lot of threads already but I wanna throw a spanner in the works with an annoying question that I hope someone will be able to answer so I can better understand the relevance of this study.https://t.co/5cE0omt6FH

— Andrew L. Croxford (@andrew_croxford) August 26, 2021

 

---

[Comunicado de imprensa – Ainda não publicado] Estudo mostra que a proteção vacinal diminui com o tempo, mas as vacinas ainda oferecem uma boa proteção contra doença grave.

30 Ago, 2021 | 12:55h

Comunicado de imprensa: Is COVID vaccine protection fading? – ZOE Covid Study

Comentários:

Covid infection protection waning in double jabbed – BBC

Expert reaction to press release from the ZOE app on vaccine effectiveness over time – Science Media Centre

---

Companhia afirma que dose de reforço com a vacina da Johnson & Johnson propicia aumento significativo na resposta imune.

26 Ago, 2021 | 12:46h

Johnson & Johnson booster shot prompts large increase in immune response, company says – CNN

Comunicado de imprensa: Johnson & Johnson Announces Data to Support Boosting its Single-Shot COVID-19 Vaccine

---

Diretrizes para a abordagem perioperatória de pacientes com câncer ovariano avançado que serão submetidas a cirurgia citorredutora.

26 Ago, 2021 | 12:12h

European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery – International Journal of Gynecological Cancer

Editorial: Standardizing ovarian cancer surgery and peri-operative care: a European Society of Gynecological Oncology (ESGO) consensus statement

---

Reforço de vacinas contra Covid-19: o que se sabe e quem está fazendo o quê.

24 Ago, 2021 | 11:52h

Covid-19 booster vaccines: What we know and who’s doing what – The BMJ

---

Opinião | O FDA realmente precisava demorar tudo isso – “Se a aprovação das vacinas parece tão escrupulosa, é porque a alternativa a isso é pior.”

24 Ago, 2021 | 11:49h

The FDA Really Did Have to Take This Long – The Atlantic

---

Vacinas contra COVID protegem da variante Delta, mas sua eficácia diminui com o tempo.

24 Ago, 2021 | 11:47h

COVID vaccines protect against Delta, but their effectiveness wanes – Nature

Estudo original: [Preprint] Pfizer vaccine effectiveness against Delta declines faster than AstraZeneca, both offering the same protection after 4 months.

---

Estudo laboratorial mostra que a estratégia de vacinação heteróloga AstraZeneca + Pfizer propicia uma imunogenicidade mais potente contra Covid comparada a estratégias homólogas AZ + AZ ou Pfizer + Pfizer.

23 Ago, 2021 | 13:16h

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study – The Lancet Respiratory Medicine

Comentário convidado: Heterologous ChAdOx1-nCoV19–BNT162b2 vaccination provides superior immunogenicity against COVID-19

Conteúdos relacionados:

Lab study shows heterologous AstraZeneca/Pfizer vaccination produces strong immune response against SARS-CoV-2 Delta variant.

RCT: Safety and immunogenicity of heterologous vs. homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine.

Another study shows increased immune response with heterologous Oxford-AstraZeneca/mRNA vaccination (vários artigos sobre o tema)

 

Comentário no Twitter

NEW Research—Heterologous ChAdOx1 nCov-19–BNT162b2 immunisation w/ 10–12-week interval is well tolerated & improves immunogenicity vs homologous ChAdOx1 nCov-19 vax w/ 10–12-week interval & BNT162b2 vax w/ 3-week interval

Study from Prof Sander & co https://t.co/VAB54NokSi pic.twitter.com/wfeBsvoKhO

— The Lancet Respiratory Medicine (@LancetRespirMed) August 13, 2021

 

---

[Preprint] Eficácia da vacina da Pfizer contra a variante Delta diminui mais rapidamente do que a da AstraZeneca; ambas oferecem a mesma proteção depois de 4 meses.

20 Ago, 2021 | 12:35h

Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK – University of Oxford

Comentários:

Vaccines Are Less Effective Against Delta—And Pfizer’s Protection Wanes Rapidly—But Are The Best Way To Protect Against Covid, Large Study Finds – Forbes

Expert reaction to preprint looking at the impact of the delta variant on vaccine effectiveness – Science Media Centre

Pfizer vaccine effectiveness declines faster than AstraZeneca – study – Evening Standard

 

Comentário no Twitter

New large UK study confirms attrition of @Pfizer vaccine effectiveness vs Delta infections over time https://t.co/K6YRyAQq4o "By roughly 4 1/2 months after the 2nd dose, Pfizer’s shot will probably be about on par with Astra’s at preventing infections with a high viral burden" pic.twitter.com/x1Nl2BkWfn

— Eric Topol (@EricTopol) August 19, 2021

 

---

Estudo do NIH mostra que não há nenhum benefício significativo do plasma convalescente para pacientes ambulatoriais de COVID-19 com sintomas iniciais.

19 Ago, 2021 | 12:29h

NIH study shows no significant benefit of convalescent plasma for COVID-19 outpatients with early symptoms – NIH News Releases

Estudo original: Early Convalescent Plasma for High-Risk Outpatients with Covid-19 – New England Journal of Medicine

 

Comentário no Twitter

Convalescent plasma did not prevent disease progression in patients seen in EDs within 7 days after the onset #COVID19 symptoms. https://t.co/9gmIK3ntKH #IDTwitter pic.twitter.com/sirzn1uGL0

— NEJM (@NEJM) August 18, 2021

 

---